SAREPTA THERAPEUTICS INC (SRPT:NASDAQ)
$20.68 -0.74 (-3.4547%)
Analysed SAREPTA THERAPEUTICS INC (SRPT:NASDAQ) News Sources
KROS 2026 Watchlist: 3 Catalysts That Could Reset Sentiment
20-04-2026
yahoo.com
KROS Rinvatercept: What to Know Before DMD Phase II Starts
20-04-2026
yahoo.com
Sarepta Therapeutics Seen Benefiting From New Elevidys Study, Better US Uptake in Second Half of 2026
17-04-2026
yahoo.com
Roche to start new Elevidys study following setback in Europe
16-04-2026
biopharmadive.com
Sarepta siRNA Data Adds New Pillar To Rare Disease Pipeline Narrative
08-04-2026
yahoo.com
How The Sarepta Therapeutics (SRPT) Investment Story Is Shifting On Mixed Elevidys And Pipeline Views
07-04-2026
yahoo.com
5 Biotechs That Big Pharma Could Snap Up as Oncology M&A Heats Up
01-04-2026
247wallst.com
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
31-03-2026
yahoo.com
MRNA, SRPT, and KRYS Phase 3 Data Will Shape XBI’s 2026 Performance
29-03-2026
247wallst.com
Why Is Sarepta Therapeutics (SRPT) Up 24.2% Since Last Earnings Report?
27-03-2026
yahoo.com
What is the current price of SAREPTA THERAPEUTICS INC (SRPT:NASDAQ)?
The current price of SAREPTA THERAPEUTICS INC (SRPT:NASDAQ) is $20.68.
SAREPTA THERAPEUTICS INC (SRPT:NASDAQ) absolute price change since previous trading day?
The absolute price change of SAREPTA THERAPEUTICS INC (SRPT:NASDAQ) since the previous trading day is $-0.74.
SAREPTA THERAPEUTICS INC (SRPT:NASDAQ) percentage price change since previous trading day?
The percentage price change of SAREPTA THERAPEUTICS INC (SRPT:NASDAQ) since the previous trading day is -3.4547%.
What is the most recent average sentiment score for SAREPTA THERAPEUTICS INC (SRPT:NASDAQ)?
The most recent average sentiment score for SAREPTA THERAPEUTICS INC (SRPT:NASDAQ) is 67 out of 100.
What is the most recent average sentiment for SAREPTA THERAPEUTICS INC (SRPT:NASDAQ)?
The most recent sentiment for SAREPTA THERAPEUTICS INC (SRPT:NASDAQ) is .
SEC-8K** Filing Available For SAREPTA THERAPEUTICS INC (SRPT:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.